Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New PR aroundVM

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Oct 24, 2021 11:15am

138 Views

Post# 34041931

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New PR aroundVM

Functional SORT1 Is Required for In Vitro Vasculogenic Mimicry

The contribution of SORT1 in the formation of 3D capillary-like structures by ES-2 ovarian cancer cells and MDA-MB-231 TNBC cells was next assessed. When SORT1 expression was repressed through specific siRNA-mediated gene silencing (Figure 4A), MMP-9 was also decreased (Figure 4B). SORT1 silencing lead to decreased 3D structures when compared to scrambled siRNA in ES-2 ovarian cancer cells (Figure 4C) and in MDA-MB-231 TNBC cells (Figure 4D). SORT1 silencing did not affect cell viability (data not shown), and this is in agreement with previous studies also showing that this did not affect cell proliferation as well (29). Quantitative analysis of the total loops formed by the cells was performed and results indicate that the number of loops was decreased by 60-90% in both cell models upon SORT1 silencing. These data confirm that SORT1 is essential for the formation of 3D capillary-like structures by MDA-MB-231 and ES-2 cells, and that a transcriptional regulation axis linking SORT1 to MMP-9, in part, explains the decreased VM.

jeffm34 wrote:
I guess the question is, how critical sortilin is to the formation of VM. Can VM occur in the absence of sortilin? If not, then the applications for TH's cancer platform are staggering.

JayjayUSA12007 wrote:
"Is it possible Theras PDC could be used as an adjunct to other chemo drugs that have reduced efficacy due to VM.

https://scholar.google.ca/scholar?q=vascular+mimicry+effects+on+cancer+treatments&hl=en&as_sdt=0&as_vis=1&oi=scholart#d=gs_qabs&u=%23p%3DhYMFxg3j3CEJ "

Only when the neuroprotein sortilin are overexpressed on cancerous tumors.
1/ Breast, lung, and thyroid cancers: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496368/
2/ Pancreatic cancer: https://ascopost.com/news/august-2020/sortilin-may-be-a-potential-therapeutic-target-in-pancreatic-cancer/

If proven via clinical trials, TH1902 and TH1904 could become a anti-cancer platform. It won't take long before a big player will attempt to take out Thera, just to own this platform.